Acro Biomedical Faces Financial Crisis with No Revenue and Growing Losses Amid Cost-Control Efforts

ACRO BIOMEDICAL CO., LTD. (PINK: ACBM)

Overview: Acro Biomedical Co., Ltd. is currently facing significant challenges. The company has not generated any revenue since December 31, 2022, and incurred large losses in its latest quarterly report for the period ending March 31, 2025. This has raised substantial doubts about the company's ability to continue as a going concern.

Positive Aspects:

• Operating expenses decreased from $10,298 in Q1 2024 to $8,934 in Q1 2025, indicating cost control efforts.
• Imputed interest from related party loans provided some financial cushion, rising to $1,367 in Q1 2025 from $954 in Q1 2024, signaling ongoing support from stakeholder financing.
• No debt reported aside from interest-bearing advances from related parties, which may imply a manageable debt situation.

Negative Aspects:

• Net loss for Q1 2025 was $10,301 compared to $11,252 in Q1 2024, showing ongoing financial distress with no revenue reported.
• Stockholder's deficit increased from $294,972 at year-end to $303,906 in Q1 2025, reflecting deterioration in financial health.
• Cash reserves have been significantly depleted, with only $251 available at the end of Q1 2025, down from $476 at the previous year-end.
• Ongoing reliance on a minority stockholder for financing, which poses risks if support is withdrawn.

Key Statistics:

• Revenue: $0
• Operating Expenses: $8,934
• Net Loss: $10,301
• Cash End of Period: $251
• Weighted Average Shares Outstanding: 60,042,000
• Stockholders' Deficit: $303,906

Conclusion: Acro Biomedical Co., Ltd. finds itself in a precarious financial position. Despite efforts to reduce expenses, the lack of revenue generation, increasing financial losses, and reliance on external financing create a challenging environment for the company's future operations. Investors should remain alert to further developments as the company seeks to recover from its current standing.